Cargando…
Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial
INTRODUCTION: Clinical guidelines recommend non-vitamin K antagonist oral anticoagulants (NOACs) over vitamin K antagonists (VKAs) for stroke prevention in most patients with atrial fibrillation (AF). Frail elderly were under-represented in the landmark NOAC-trials, leaving a knowledge gap on the op...
Autores principales: | Joosten, Linda P T, van Doorn, Sander, Hoes, Arno W, Nierman, Melchior C, Wiersma, Nynke M, Koek, Huiberdina L, Hemels, Martin E W, Huisman, Menno V, Roes, Kit C, van den Bor, Rutger M, Buding, Wim F, Rutten, Frans H, Geersing, Geert-Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937027/ https://www.ncbi.nlm.nih.gov/pubmed/31888928 http://dx.doi.org/10.1136/bmjopen-2019-032488 |
Ejemplares similares
-
Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
por: Giugliano, Robert P
Publicado: (2022) -
Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis
por: Joosten, Linda P T, et al.
Publicado: (2023) -
Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
por: Camilleri, Eleonora, et al.
Publicado: (2021) -
Increased risk of volume overload with plasma compared with four‐factor prothrombin complex concentrate for urgent vitamin K antagonist reversal
por: Refaai, Majed A., et al.
Publicado: (2015) -
The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists()
por: Visser, Chantal, et al.
Publicado: (2023)